Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that offers discovery and development of innovative treatments. The company discovers and develops treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Its product pipeline is being generated from the company’s proprietary RNA interference. Dicerna’s product pipeline comprises DCR-PH1, KRAS Program, primary hyperoxaluria 1 and hepatocellular carcinoma. The company provides RNAi-targeted drugs, delivery systems and DsiRNA molecules. It also offers traditional therapeutic modalities, such as small molecules and monoclonal antibodies. The company offers its drug discovery and development activities that are based on the therapeutic modality of RNAi. Dicerna is headquartered in Cambridge, Massachusetts, the US. GlobalData’s Dicerna Pharmaceuticals Inc (DRNA) - Financial and Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering world’s leading companies.